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Abstract 
Huntington’s disease is an autosomal-dominant disease characterized by deterioration in motor, 
cognitive, and emotional function. The majority of research has focused primarily on the motor 
symptoms associated with Huntington’s disease. However, more recent findings show that many 
Huntington’s patients develop psychological symptoms, such as depression, a decade before they 
experience motor symptoms or are aware that they have the fatal neurodegenerative disease.  
Using a Huntington’s disease transgenic mouse model, we explored the hypothesis that the 
hippocampus plays a role in depression that manifests in Huntington’s patients before the 
diagnosis and motor dysfunction. Clinical research suggests that people with depression have 
significantly decreased levels of neurogenesis in the dentate gyrus of the hippocampus. Here we 
use an experimental technique known as RNA interference (RNAi) to decrease the amount of 
toxic mutant huntingtin protein (mHtt) in transgenic Huntington’s mice. Due to the knockdown 
of mHtt, we hypothesized that the RNAi treatment would make the hippocampus more 
hospitable to cell division and cell survival. Therefore, the rate of neurogenesis would improve in 
the dentate gyrus of the hippocampus. In addition, if neurogenesis is involved in depressive-like 
symptoms, we predicted that we would see a decrease in depressive-like behavior. Using 
stereotaxic surgical techniques, RNAi gene constructs encapsulated in adeno-associated viral 
capsids (AAV 2.4) were injected directly bilaterally into the brain, targeting the dentate gyri of 
transgenic huntingtin mice. The RNAi constructs were allowed to express RNAi over a 12-week 
period in which a variety of behaviors were evaluated. Following behavioral testing, brain tissue 
was examined for cellular changes using immunohistochemistry techniques to visualize 
Doublecortin (DCX), a protein involved in neuronal migration. Animals treated with RNAi 
exhibited a small, but significant, improvement in the hole board memory task as compared to 
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control animals. Additionally, analysis of immunochemical staining for DCX indicated a 
significant decrease in the number of DCX positive cells found in the RNAi-mHtt hippocampal 
tissue. In short, the results suggest that RNAi treatment of the dentate gyrus can elicit subtle 
changes in memory and hippocampal neurogenesis in transgenic mice expressing the human 
mutant huntingtin gene.   
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Elucidating the cause of depression in Huntington’s disease: Effects of reducing mutant 
huntingtin protein production in the hippocampus on neurogenesis 
 Huntington’s disease is an “autosomal dominant terminal illness characterized by 
deterioration in motor, cognitive, and emotional function.” (Paulsen et al., 2005, p. 497). 
Individuals with Huntington’s disease have an abnormal number of trinucleotide cytosine-
adenosine-guanine (CAG) repeats in the IT-15 gene on chromosome 5. An individual with more 
than thirty-six CAG repeats in gene IT-15 has Huntington’s disease.  Longer CAG repeats often 
correspond to earlier disease onset. The IT-15 gene codes for the specific protein huntingtin. The 
mutated gene with extra CAG repeats codes for the production of mutant huntingtin protein 
which is both toxic to cells and fails to function properly leading to cell death in areas such as the 
striatum of the basal ganglia and cortical regions (Zuccato, et al., 2010).  
 Since the disease is autosomal-dominant, an individual with Huntington’s disease has a 
fifty percent chance of passing the disease on to their offspring. The onset of the disease is 
usually between the ages of thirty to fifty. Early symptoms of Huntington’s disease include 
depression, hypersexual behavior, weight loss, and sleep disturbances. As the disease progresses, 
symptoms include dementia, motor symptoms, and impaired judgment. Debilitation due to 
Huntington’s disease is due to a combination of psychiatric issues paired with motor and 
cognitive deficits. (Soliveri, Monza, Piacentini, & Paridi, 2002). Most patients with Huntington’s 
disease die from aspiration pneumonia due to impaired swallowing (Zuccato et al., 2010). 
 Huntington’s disease was first systematically analyzed and studied by Dr. George 
Huntington in 1872. Huntington wrote “On Chorea” describing the symptoms and neural 
pathology of the disease. However, he was unsure what brain regions were affected and what 
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was causing the degeneration. The paper was titled “On Chorea” due to the primary symptom 
exhibited by individuals with the disease. Huntington wrote, “The name ‘chorea’ is given to the 
disease on account of the dancing propensities of those who are affected by it, and it is a very 
appropriate designation […] its most marked and characteristic feature is a chronic spasm 
affecting the voluntary muscles” (Huntington, 2003, p. 109). Huntington noted that the disease 
also caused mental issues and that those suffering from Huntington’s disease exhibited 
depressive-like symptoms. He wrote, “I know of several instances of suicide of people suffering 
from this form of chorea […] as the disease progresses the mind becomes more or less impaired, 
in many amounting to insanity” (Huntington, 2003, p. 109). 
 While George Huntington outlined the mental deficits, they are only recently being 
studied in depth. The most common psychiatric symptom of Huntington’s disease is depression. 
Although the development of depression in individuals with neurological diseases has been 
found to be influenced by multiple variables including psychosocial factors, it is now clear that 
in Huntington’s disease biological factors such as brain pathology play a significant role in the 
manifestation of depression (Paulsen et al., 2005).  
 Depression incidence is high in people who have Huntington’s disease, and depression 
peaks during the early stages of the illness, prior to the manifestation of motor abnormalities. A 
study by Folstein et al. (1983) found that depression incidence was 41% in Huntington’s patients. 
Huntington’s patients also have an increased rate of suicide (5-10%) and suicide attempts (25%) 
(Walker, 2007). Research indicates that suicide rates for individuals with Huntington’s disease is 
over five times higher than the general population. Paulsen’s work indicated that forty-percent of 
participants with Huntington’s disease had current depressive symptoms, fifty-percent had 
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received treatment for depression, and ten-percent had made suicide attempts (Paulsen et al., 
2005). 
  Originally, it was thought that the depressive symptoms were explained by the 
psychological trauma of a terminal illness diagnosis and the subsequent cognitive and motor 
decline. However, research indicates that often times the psychiatric symptoms occur before the 
motor symptoms in Huntington’s disease (Lundh, Nilsson, Soylu, & Kirik, 2013). This suggests 
that early changes in brain structure and function may be the cause of depression in Huntington’s 
disease. One aspect of this study is to examine the hippocampal brain pathology, in terms of 
neurogenesis, in a transgenic Huntington’s disease mouse model.  
 Researchers have used transgenic rodent models of Huntington’s disease to better 
understand the neuropathology as well as potential treatment options. Studies of transgenic 
Huntington’s disease mice have shown that changes in gene expression are involved in anxiety 
and depressive like behaviors (Lundh et al., 2013).  In a study conducted by Lanfumey and 
colleagues (2000), serotonin (5-HT) knockout directly affected hypothalamo-pituitary-adrenal 
dependent response to stress. Additionally, reduced glucocorticoid receptor function in mice 
causes clinical disturbances as seen in depression. Subsequent treatment with moclobemide, an 
antidepressant, reduced the depressive-like symptoms (Montkowski et al., 2006). Taken together, 
serotonin signaling appears to play a role in the depressive-like behavior observed in transgenic 
Huntington’s disease mice.  Moreover, selective serotonin uptake inhibitors such as fluoxetine 
appear to promote the survival and differentiation of new neurons through neurogenesis and have 
positive effects on Huntington’s disease transgenic mice as indicated by behavioral and 
histological effects (Grote, Bull, Howard, & van Dellen, 2005). It has also been discovered that 
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antidepressants can cause an increase in Brain Derived Neurotropic Factor (BDNF) levels and 
increase neurogenesis in a transgenic Huntington’s disease mouse model (Peng et al., 2008).  
 Other research avenues have suggested that neurogenesis, the birth of new neurons, may 
also play a role in depression.  While it was previously thought that individuals were born with 
the total number of neurons that they would have in their entire lifetime, research has shown that 
this is not the case. Eriksson and colleagues (1998) found in the adult human brain that 
neurogenesis occurs from dividing progenitor cells found in the hippocampus. The subgranular 
zone is the primary location of neurogenesis in the hippocampus (Miller et al., 2013) and clinical 
studies have suggested a link between decreased levels of neurogenesis and depression. Jacobs et 
al. (2000) proposed that stress leads to decreases in dentate gyrus neurogenesis and that this 
decrease may be a primary factor in eliciting episodes of depression. Research also suggests that 
antidepressants promote neurogenesis (Malberg, Eisch, Nestler, & Duman, 2000). Decreased 
neurogenesis might be one of the causes of depression considering the negative effects of stress 
on neurogenesis and the fact that neurogenesis is necessary for the action of antidepressants 
(Henn & Vollmayr, 2004). Although neurogenesis seems to affect depression, most likely the 
cause of depression is multifactorial. Thus, more research is necessary to elucidate the role of 
neurogenesis in depression.  
  Several transgenic Huntington’s mouse models have been used to study the effects of 
neurogenesis on depressive-like behavior and anxiety. M’Barek et al. (2013) found that adult 
hippocampal neurogenesis has an effect on anxiety and depression-like symptoms in transgenic 
mice. Such results have prompted researchers to propose that finding ways to encourage 
neurogenesis could potentially be a viable strategy for treating depression (Sahay et al., 2011). 
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 Brain Derived Neurotrophic Factor (BDNF) is a secreted protein that is a part of the 
neuroptropin growth factor family. These proteins help promote the survival of new neurons as 
well as stimulate their growth. Research shows that mHtt results in decreased production of 
BDNF (Zuccatto et al., 2001). This causes insufficient neurotrophic support for neurons and 
ultimately leads to their death from Huntington’s disease. This suggests that increasing BDNF 
and decreasing mHtt levels could be a therapeutic approach for treating Huntington’s disease 
(Zuccatto et al., 2001). A study of transgenic Huntington’s mice by Simmons et al. (2009) 
looked at the effects of up-regulating BDNF on plasticity and learning. He found that an up-
regulation of BDNF offset the impairments of long-term memory. Research has also found that 
the generation and survival of new neurons can be increased with the injection of exogenous 
BDNF (Zigova, Pencea, Weigand, & Luskin, 1998). Based on these findings, we hypothesized 
that decreasing the expression of mHtt in the hippocampus might increase the production of 
BDNF. Subsequently, increased BDNF levels might result in increased neurogenesis and 
decreased depressive-like symptoms observed in transgenic Huntington’s disease mice. To 
reduce mHtt expression in the hippocampus we used RNAi.   
 One of the most recent treatment options for Huntington’s disease that is under 
exploration is RNA interference. RNAi can regulate the expression of protein coding genes such 
as the IT-15 gene, which codes for the huntingtin protein (Htt).  In the case of Huntington’s 
disease, the goal would be for the RNAi to stop the expression of the mutant huntingtin protein 
and thus stop the progression of the fatal neurological disease. In a study by Harper et al. 
(2005a), RNAi reduces Htt mRNA and protein expression in the brain of transgenic 
Huntington’s disease mice. Also the Htt gene silencing, due to RNAi, improves both behavioral 
and neuropathological abnormalities associated with Huntington’s disease.  This suggests that 
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even partial reduction of the mutant Htt expression can improve symptoms of Huntington’s 
disease (Harper et al., 2005a). 
 The purpose of the present study was to examine the effects of RNAi on hippocampal 
neurogenesis and depressive-like symptoms in a transgenic mouse model of Huntington’s 
disease.  We hypothesized that RNAi injected directly into the hippocampal dentate gyrus would 
decrease depressive-like symptoms and increase neurogenesis indicated by the presence of DCX 
positive cells.  
Method 
Animals  
 The 34 mice used in the study were the offspring of two N171-82Q males and six B6C3 
females obtained from Jackson Laboratories (Maine, USA). Of the offspring, 26 were confirmed 
N171-82Q and 8 were B6C3F2 wild type (17 male, 17 female). All mice were housed in the 
Small Laboratory Animal Unit (SLAU) at the Oregon National Primate Research Center in 
Beaverton, OR and kept on a 12-hour-light-dark cycle with food and water provided ad libitum. 
All were group-housed in cages containing 2-5 mice of the same sex. All experiments were 
performed with Institutional Animal Care and Use Committee approval from the Oregon Health 
& Science University/Oregon National Primate Research Center and in accordance with both 
federal and institutional guidelines (IS00001737).  
Intra-cranial Stereotaxic Surgeries 
 Intra-cranial stereotaxic surgeries were performed under isoflurane gas vaporized in 
100% oxygen. A 33-guage blunt needle connected to a 10 µl Hamilton syringe was lowered 
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stereotaxically at a 90-degree angle to the surface of the skull into the dentate gyrus of the left 
and right hippocampi. Two injections at 1 µl over 10 minutes were made of either AAV-2.4 
RNAi eGFP or AAV control eGFP, at the coordinates at the level of the skull: 
Anterior/Posterior: -2 mm, Medial/Lateral: ± 1.5 mm, Dorsal/Ventral: -2.3 mm. After each 
injection, the needle was left in situ for an additional 4 minutes to allow for diffusion of solution 
from the needle tip. Then the needle was slowly retracted and realigned to perform the second 
injection. After the second injection and 4 minutes in situ, the needle was slowly retracted and 
the wound was closed with a 5-0 polyvicryl suture. Each animal received carprofen injections 
(0.1 ml) to reduce pain for the following 2 days. 
Behavioral Testing 
 Five behavioral tasks were chosen to assess 1) depression-related, 2) stress-related, and 3) 
coordinated locomotor behaviors. The tests included accelerated rotarod, stress-induced 
hyperthermia, tail suspension test, forced swim test, hole board. Body weight was measured 
every week while each behavioral test was administered once every two-week period. All 
behavioral tests occurred during the light cycle (between 8:00 am and 5:00 pm). All 
experimenters were blinded to the treatment group during the course of the study.  
Accelerated Rotarod 
 Motor coordination and balance were measured by utilizing an accelerating rotarod (Ugo 
Basile, Comerio, Italy). For baseline data, mice underwent three test trials prior to surgery. 
Following surgery, mice were tested once every two-week period throughout the duration of the 
study. The rotating rod accelerated from 5 to 40 rpm over a 4-minute period. Each mouse 
underwent three consecutive trials with resting periods of 30 minutes between each trial. The 
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average latency to fall from the rotarod was calculated from the latencies gathered from the three 
trials. On the occasion that a mouse would cling to the rotarod, three consecutive rotations would 
immediately end the trial (Cummings et al., 2012) (Figure 1.2).  
Forced Swim Test 
 Depressive-like behavior was measured using the forced swim task, executed as 
described by Porsolt et al. (1977, 1978). Mice were gently placed into a 3.7 L glass container 
(height: 18.5 cm; diameter: 18 cm) filled with 13 cm of water (temperature: 24 ±1 °C). 
Following the initial 60 seconds of the 6-minute trial, the experimenter recorded bouts of 
immobility in every 5-second period. Immobility was defined as the as the cessation of limb 
movements with the exception of minor, involuntary movements of the hind limbs or other 
movements necessary to stay afloat. After completion of the trial, mice were gently dried and 
returned to their home cage. Immobility was calculated as a percentage of the number of 
instances immobile ([time of observed immobility / 60 (total time)] • 100) and then converted 
into ratios for statistical analysis (immobility pre-surgery / immobility of trial) (Carroll et al., 
2007; Ihn et al., 2012) (Figure 1.3).  
Stress-Induced Hyperthermia/Tail Suspension Test 
 Stress reaction was evaluated using the stress-induced hyperthermia and tail suspension 
tests. Body temperature was taken rectally using a RET-3 thermocouple probe and BAT-12 
thermometer (Physitemp, New Jersey). Mice were gently restrained by holding each mouse at 
the base of the tail and around the haunches. Temperature was taken by inserting a probe 
lubricated with petroleum jelly 2 cm into the rectum. A constant reading was obtained in 10-15 
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seconds. Mice were then suspended by the tail at a height of 30cm for 6 minutes in order to 
induce stress and time immobile was recorded using a stopwatch.  
After the tail suspension test, as described by Steru et al. (1985) and Liu et al. (2003), 
temperature readings were taken at 0 min [T1], 6 min [T2], and 21 min [T3]. Mice were returned 
to their home cage and the difference in temperature between T3 and T1 (T3 – T1) was used to 
measure stress-induced hyperthermia (van Der Heyden et al., 1997; Slawinska et al., 2012) 
(Figure 1.4).  
Hole Board 
 Memory was assessed using a 2-day hole board paradigm. Mice were placed in a 40 cm2 
Plexiglas container that had a floor with sixteen 1.5-cm holes organized in a 4x4 fashion (first 
described in File & Wardill, 1975). The cage connected to a computer system recording 
locomotion and hole investigation via infrared photo beams located at 1 cm above the floor and 
just inside each hole to detect nose pokes, respectively. Each hole had inaccessible chocolate 
pellet treats underneath a mesh floor; accessible chocolate pellet treats were placed randomly in 
one hole per row (1g pellets obtained from TestDiet). Every two weeks, mice were given a day 1 
habituation trial consisting of four consecutive 3-minute runs with new treat placements each 
week. The following day, mice were placed in the containers with the same treat pattern and 
underwent four consecutive 3-minute test trials. Data was collected in a ratio of correct hole 
pokes / total number of hole pokes during day 2 exposure to the hole board (Figure 1.5).  
Necropsy 
 Mice were anaesthetized with an overdose of ketamine-xylazine solution. Those 
predetermined for immunohistochemical use were perfused transcardially with 15 ml of 0.9% 
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sterile sodium chloride saline followed by 15 ml of 4% paraformaldehyde. Brains were removed 
and post-fixed in 4% paraformaldehyde for 24 hours, then switched to 30% sucrose solution. 
These brains were frozen using dry ice and sliced on a sliding microtome into 40 µm sections.  
Injection Placement 
 The site of the tip of the injection needle and the diffusion of the AAV2/1 RNAi eGFP 
were confirmed by either 1) immunohistochemical visualization of coronal slices or 2) qPCR 
analysis of the expression of mHtt in the DG tissue punches. Roughly half of the mouse brains 
were perfused, fixed in 4% paraformaldehyde, frozen using dry ice and sliced on a sliding 
microtome into 40-micron sections. Tissue was assessed through light and fluorescent 
microscopy to visualize spread of the RNAi (eGFAP) and, after basic immunohistochemical 
staining procedures (see details below), to visualize new neurons (BrdU), and immature neurons 
(DCX). Nuclei and fiber tracts were identified using the mouse atlas by Franklin and Paxinos 
(2008). The remaining brains were appointed for qPCR analysis, and so the mice were perfused 
with ice-cold saline, the brains rapidly removed, and the DG carefully dissected out and frozen in 
dry ice.  
Immunohistochemistry to detect Neurogenesis 
 Bromodeoxyuridine (BrDU) has been the gold standard for marking neurogenesis. BrDU 
is a thymine analog that can incorporate itself into the DNA during DNA synthesis. It is also 
passed on to the daughter cells (Wojtowicz & Kee, 2005). However, research has been 
conducted to uncover alternative measurements for neurogenesis such as Doublecortin (DCX). A 
study conducted by Couillard-Despres et al. (2005) demonstrated that DCX is legitimate 
alternative technique to measure neurogenesis levels. DCX is a protein that is expressed in 
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differentiating and migrating neurons (Francis et al., 1999). DCX is necessary for the migration 
of neurons from the hippocampus to the cerebral cortex. It is also associated with brain 
microtubules and co-assembles with the microtubules. Research suggests that DCX regulates the 
stability and organization of microtubules and directs neuronal migration (Gleeson, 1999). A 
study conducted by Bai et al. (2003) examined the cellular role of DCX in rats. Their research 
suggests that DCX is necessary for neuron radial migration to form the neocortex. In this study 
we are staining for DCX to examine neurogenesis over the last 2-3 weeks of life in the dentate 
gyrus of the hippocampus in mHtt mice.  
 Free floating coronal brain slices (40µ) were processed for fluorescence DCX detection. 
The first day, coronal brain sections were washed in dilution media in netted staining dishes 5 x 
5 minutes. Sections were then blocked in 5% donkey serum in netted staining dishes for 1 hour. 
Sections were incubated in primary antibody (DCX 1:200, Rabbit anti Doublecortin, ab77450, 
Abcam) solution in ceramic dishes and left on an orbital shaker for 24 hours. The second day, the 
sections were washed in dilution media in netted staining dishes 5 x 5 minutes. Then the sections 
were incubated in fluorescent secondary antibody (1:200, AMCA-conjugated donkey anti rabbit 
IgG (H+L), Jackson ImmunoResearch) solution in covered ceramic dishes on orbital shaker at 
room temperature for 1 hour. The sections were washed in TBS in netted staining dishes 3 x 5 
minutes. Then the sections were stored at 4 degrees in PBS in covered netted staining dishes 
until mounted on microscope slides (Colorfrost Plus, Fischer Scientific). Sections were placed on 
slides and coverslipped (Thickness: 1.5microns, Fischer Scientific) using Prolong Gold Antifade 
coverslip solution (Prolong (R) Gold Antifade Reagent, Cell Signalling).  
Data Analysis 
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 To analyze the hippocampal brain slices, images were captured using an Olympus BX60 
Fluorecent microscope. Images were then analyzed using Fiji, Image J to enhance images for cell 
counts. Cell counts were done by hand employing a rectangular template (12cm x 5 cm) to ensure 
a consistent area of the hippocampus was being analyzed for neurons containing DCX .  
Results 
Body Weight 
A two-way mixed analysis of variance (ANOVA) showed there was a significant main 
effect of group on body weight [F(3,28) = 3.95, p < 0.05]. Similarly, statistics suggest a 
significant main effect of time point [F(13,14) = 183.397, p < 0.05] as well as a significant 
interaction of group x time point [F(39,264) = 12.897, p < 0.05].  
 LSD post-hoc analysis revealed that both mHtt animals treated with RNAi (mean = 19.5) 
and mHtt animals treated with control solution (mean = 19.97) were significantly lighter than 
wildtype littermates treated with RNAi (mean = 23.959) (Figure 2.1).  
Rotarod 
A two-way mixed ANOVA of performance on the accelerating rotarod suggested a 
significant main effect of group [F(3,28) = 4.39, p < 0.05]. Though there was no significant main 
effect of trial found [F(4,5) = 2.29, p > 0.05], results suggested a significant interaction between 
trial and group [F(12,112) = 3.05, p < 0.05].  
LSD post-hoc analysis showed that both the mHtt treated group (mean = 130.45) and the 
mHtt control group (mean = 125.295) performed significantly worse than the WT control group 
(mean = 166.13). However, there was no significant difference between the mHtt animals that 
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received the RNAi treatment and those mHtt animals receiving control solution. Finally, data 
from week 9 was removed from analysis due to an abnormal increase in performance across all 
groups (Figure 2.2). 
Forced Swim Task 
Values for the FST were converted into ratios before statistical analysis (formula: value 
of week # / value at presurgy trial) in order to remove variability due to extreme differences 
between groups prior to surgical treatment. A two-way mixed ANOVA did not indicate a 
significant main effect of group [F(3,28) = 0.57, p > 0.05]. Additionally, no significant main 
effect of trial was found [F(5,6) = 1.36, p > 0.05] nor a significant interaction of group x trial 
[F(15,140) = 1.02, p > 0.05] (Figure 2.3).  
Stress-Induced Hyperthermia 
A two-way mixed ANOVA showed no significant main effect of group [F(3,30) = 2.68, p 
> 0.05] as well as no significant main effect of trial [F(5,6) = 0.70, p > 0.05]. Additionally, no 
significant interaction was found of group x trial [F(15, 150) = .51, p > 0.05] (Figure 2.4).  
Tail Suspension Task 
Similar to values for FST, data collected from TST was converted into ratios using the 
same formula (week # / presurgical value) to eliminate variability between groups in the 
presurgical trial. A two-way mixed ANOVA did not show a significant main effect of group 
[F(3,30) = 0.20, p > 0.05] nor a significant main effect of trial [F(5,6) = 1.66, p > 0.05]. No 
significant interaction of group x trial was found [F(15,150) = 0.25, p > 0.05] (Figure 2.5).  
Hole Board 
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 A two-way ANOVA revealed a significant main effect of group [F(3,28) = 3.81, p < 
0.05], however there was no significant main effect of trial [F(4,5) = 0.35, p > 0.05]. Moreover, 
no significant interaction of group x trial was found [F(12,112) = 0.94, p > 0.05].  
 LSD post-hoc analysis showed that the mHtt animals that received control solution (mean 
= 0.38) had significantly less correct hole pokes than both the wildtype animals treated with 
RNAi (mean = 0.497) and the wildtype animals receiving control solution (mean = 0.47). 
However, no significant difference was detected between the mHtt RNAi treated group and the 
mHtt control group (Figure 2.6).   
Immunohistochemistry 
A One Way ANOVA for Independent Groups indicated that there were significant 
differences in the DCX counts among the three groups. F(2,151) = 7.026, p < 0.05.  Tukey’s post 
hoc analysis revealed that the RNAi-mHtt group was significantly lower than the PBS-mHtt and 
PBS-wildtype groups (mean for RNAi-mHtt=9.5143, mean for PBS-mHtt=10.6429, mean for 
PBS-wildtype=10.8036) (Figure 3.1).  
Discussion 
 As predicted, a significant difference in the number of DCX positive cells was found 
between the RNAi treated-mHtt group, the control-wildtype, and control-mHtt groups. However, 
we failed to correctly predict the pattern of differences between groups. Surprisingly, the RNAi 
treated-mHtt group exhibited decreased levels of neurogenesis when compared to the control-
mHtt group (Figure 3.1). Prior to this experiment, no other studies have reported the rate of 
neurogenesis in N171-82Q mice.  
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In a related study, where BrDU levels were examined to indicate neurogenesis, we were 
surprised to learn that these transgenic Huntington’s disease mice exhibit an increase in 
neurogenesis and that this increased rate of neurogenesis is associated with impaired memory on 
the Hole board task. Despite this, our RNAi treatment significantly reduced the abnormally high 
levels of neurogenesis, bringing the rate down to the level of control-wildtype mice.  
 It was thought that an up-regulation of neurogenesis was desirable. However, some 
evidence suggests that there is a threshold of the amount of neurons that are ideal. In fact, there 
are cases when too much neurogenesis causes problems. Adults are unable to recall memories 
from their earliest childhood experiences. Scientists have called this phenomenon infantile 
amnesia. This has puzzled researchers because the brain’s capacity for learning is exceptionally 
high during this period. Josselyn and colleagues (2012) have researched the mechanism behind 
infantile amnesia and assert that the newfound biological explanation is high rates of 
neurogenesis in the hippocampus. There seems to be a connection between high levels of 
hippocampal neurogenesis in infants and their inability to form enduring memories. The decline 
of hippocampal neurogenesis in infants corresponds with the ability for them to form long lasting 
and stable memories. The researchers proposed that high levels of neurogenesis inhibit the ability 
to form lasting memories by replacing synaptic connections in preexisting memory circuits  
(Josselyn, 2012). We hypothesized that the RNAi treatment would up-regulate neurogenesis and 
thus the behavioral data would show improvement in behavioral tasks such as memory. The 
RNAi-mHtt group showed improved memory, which supports part of our hypothesis; however, 
the better memory corresponded to lower levels of hippocampal neurogenesis.   
 RNAi has been shown to directly reduce disease gene expression. Research has been 
conducted to determine if RNAi is tolerated in a healthy brain. Injections of RNAi into the 
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striatum suggest that healthy brains can tolerate RNAi. A study conducted by Harper and 
colleagues proposed RNAi as a viable treatment option for Huntington’s disease. They found 
that the RNAi treatment directly reduces the mutant gene expression, improves motor and gait 
abnormalities, and prevents protein aggregate formation in Huntington disease mouse models. 
(Harper et al., 2005b). Since RNAi decreases gene expression, we hypothesized that the 
treatment would lead to a higher level of neurogenesis in the hippocampus than the control-mHtt; 
however, our results did not support this hypothesis. To date, RNAi studies have been conducted 
in the striatum; however, no studies have been conducted looking at the effect of RNAi on 
neurogenesis in the hippocampus. Although previous studies have shown that RNAi treatment 
does not have a toxic effect on the brain, there is a possibility that it could be toxic to the unique 
cells in the dentate gyrus of the hippocampus. If the hippocampal cells could not tolerate the 
treatment due to toxicity, the results would indicate a decrease in the number of DCX positive 
cells.  
 There are several alternative explanations for the current results. First, an increase in 
neurogenesis in the control-mHtt animals could be part of a compensatory response to increase 
the number of new neurons due to the death of neurons from the mHtt protein. Or, in fact, the 
RNAi could be having a toxic effect on the hippocampal cells in the dentate gyrus causing a 
decrease in neurogenesis. However, no evidence for RNAi toxicity has been found.  
 Another alternative explanation for the decrease in DCX positive cells in the RNAi-mHtt 
group is that DCX is sensitive to a decrease in normal huntingtin protein (Htt). RNAi reduces 
both normal and mutant huntingtin expression. RNAi has not been engineered to differentiate 
between Htt and mHtt. The amount of gene expression that is silenced is unknown. Studies have 
shown that a reduction in Htt and mHtt expression from RNAi treatment has resulted in a 
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reduction in both motor and neuropathological abnormalities in a Huntington’s disease mouse 
model (Harper, 2005). DCX could be highly sensitive to reductions in normal huntingtin protein. 
If DCX needs huntingtin, we would predict a reduction in staining indicating less DCX positive 
cells. 
 Future research interests include looking at other proteins in the hippocampus involved in 
neurogenesis and depression such as detecting BDNF levels. Research indicates that mHtt down-
regulates BDNF. Hippocampal tissue could be analyzed to examine BDNF levels and determine 
if they are increased or decreased with RNAi treatment. Research also suggests that serotonin 
released into the hippocampus may drive BDNF levels, so looking at serotonin levels could be 
another aim (Martinowich, & Lu, 2007). 
 Several limitations of the experiment could have contributed to our intriguing results. 
DCX might not be a sensitive measure of neurogenesis. Thus, more research on the effectiveness 
of DCX as an indicator for neurogenesis should be conducted. Also neurogenesis in transgenic 
mice has not been researched using the BACHAD mouse model. Maybe another transgenic 
mouse model that has more similar neurogenesis patterns as humans could be used.   
In short, while these significant results are intriguing, it is important to point out that the 
actual effect size between groups is very small, amounting to only a few positive DCX fibers per 
slice. Similarly, the behavioral results, also statistically significant, are only robust at one time 
point. Consequently, while we believe that these findings are important and suggest that RNAi 
may prove to be a viable strategy for improving cellular dysfunction, much more work is 
necessary to elucidate the precise doing and injection parameters.  
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Appendix A 
Figures 1.1-1.6 
 
 
 
 
 
 
Figure 1.1. Stereotaxic surgery performed on all animals while under isofluorine anesthesia. 
Injections were made at a 90° angle at the following coordinates at the level of the skull: 
Anterior/Posterior: -2 mm, Medial/Lateral: ± 1.5 mm, Dorsal/Ventral: -2.3 mm.  
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Accelerating rotarod assessed locomotor abilities. Over a 4-minute period, the rotarod 
would accelerate until mice were no longer able to stay on the rotating rod or clung to the rod for 
more than 3 full rotations.  
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Figure 1.3. Forced swim task was completed in a clear cylindrical jar filled with 6 inches of 
water. Mice were placed in the jar for 6 minutes; mice were allowed 1 minute of habituation then 
bouts of immobility were recorded for 5 minutes.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Stressed was induced by hanging mice by their tail for 6 minutes. Temperatures were 
recorded directly before, directly after, and 15 minutes after to measure transient changes in body 
temperature. Time immobile was calculated during the whole 6-minute period 
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Figure 1.5. Infrared photo beams recorded hole poke and locomotion in the hole board cages. 
Each trial consisted of a day 1 habituation period and a day 2 testing period.  
 
 
 
 
 
 
 
 
 
 
Figure 1.6. Animals were perfused intracardially with ice-cold saline and paraformaldehyde. 
Their brains were harvested and either stored in 30% sucrose solutions or placed into an ice-cold 
matrix for removal of tissue for RT-qPCR analysis.   
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Appendix B 
Figures 2.1-2.6 
 
Figure 2.1. Average body weight (grams) of animals during lifespan. Wildtype animals treated 
with RNAi were significantly heavier than both mHtt RNAi-treated animals and mHtt control 
animals.  
 
 
Figure 2.2. Average recording of latency to fall (seconds) from pre-surgery to 15 weeks of age. 
Wildtype controls had a significantly longer latency to fall than both mHtt RNAi mice and mHtt 
saline-injected mice starting at week 11.   
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Figure 2.3. Recordings of bouts of average immobility reported in ratios ( # / presurgical #) from 
presurgery to 15 weeks of age. There was no significant difference in average immobility 
between groups.   
 
 
Figure 2.4. Difference in core body temperature (°F) before and after stress-inducing situation 
(Temperature 15 min after completion of task – temperature immediately prior to test). No 
significant difference was found in average temperature change between groups.  
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Figure 2.5. Average bouts of immobility reported in ratios ( # / presurgical #). No significant 
difference was found in average time immobile between groups.  
 
 
 
Figure 2.6. Average number of correct hole pokes. mHtt control animals performed significantly 
worse than both wildtype animals treated with RNAi and wildtype control animals at the (first 
and?) last time point.   
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Appendix C 
Figure 3.1 
 
 
Figure 3.1. Average number of DCX neurons. RNAi-mHtt animals showed significantly fewer 
DCX neurons than the Control-wildtype and Control-mHtt animals.  
 
Figure 3.2 
 
Figure 3.2 DCX positive cells in the dentate gyrus of the hippocampus in 1) RNAi-mHtt, 2) 
Control-mHtt, 3) Control-Wildtype mice.   
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